GlassScriptPhysician profile
David G Judd
NPI 1508112491
$3,119.66
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,077 · 2022: $43.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,842.69 | 2021 | |
| Neurocrine Biosciences, INC. | $333.67 | 2021 | |
| Sunovion Pharmaceuticals INC. | $270.47 | 2021 | |
| Abbvie INC. | $206.09 | 2021 | |
| Vanda Pharmaceuticals INC. | $172.20 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.58 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $74.90 | 2021 | |
| Indivior INC. | $41.20 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $25.49 | 2021 | |
| Lundbeck LLC | $11.81 | 2021 | |
| Noven Therapeutics, LLC | $11.56 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Judd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.